The FDA has granted a priority review designation to a supplemental biologics license application and supplemental new drug application for nivolumab (Opdivo) plus cabozantinib (Cabometyx) for the treatment of patients with advanced renal cell carcinoma.
The paradigm of advanced nonsquamous non–small cell lung cancer (NSCLC) is now one that necessitates discussions regarding the use of combination chemoimmunotherapy, combination immunotherapy, and single-agent immunotherapy, explained Jonathan Dowell, MD.
The investigational CAR T-cell product AUTO3 in combination with pembrolizumab (Keytruda) was found to have a tolerable safety profile and elicit durable complete responses (CRs) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to results of the single-arm, phase 1/2 ALEXANDER study that were presented during the virtual 2020 ESMO Congress.
The advent of immunotherapy has revolutionized multiple areas of cancer treatment, said Timothy Cragin Wang, MD, who added that the transformative potential of the modality has been mild at best in the field of colorectal cancer (CRC).
Despite encouraging data shown in some subtypes, there is still a lot of work that still needs to be done with regard to determining the optimal use for immunotherapy in patients with sarcoma, a population that has historically been difficult to treat.